Non-Small Cell Lung Cancer - Immunotherapies

Description

This report delves into the evolving landscape of NSCLC treatments, focusing on insights from 12 key opinion leaders in the USA and Europe. It explores the growing trend of neoadjuvant and perioperative IO-based regimens, with Opdivo and Keytruda becoming standard in the US and Europe. The report highlights the need for better prognostic markers to refine patient selection for IO-based adjuvant therapy. It also examines the potential of Summit's ivonescimab as a novel therapy and the exciting prospects for mRNA-based vaccines like Moderna's V940. Pharmaceutical professionals will gain a comprehensive understanding of current and future treatment pathways.

Key questions answered:

What are the preferred IO-based regimens for early-stage, locally advanced, and metastatic NSCLC?
How has the use of approved immunotherapies evolved, and what are the future trends?
Which clinical trials of immunotherapies have the potential to significantly impact treatment practice?
What are the most promising pipeline immune therapies, and how might they affect current market players?
How is the NSCLC immunotherapy treatment landscape expected to change in the near to medium term?
What are the key clinical data and trials shaping the current treatment algorithm for NSCLC?

Key brands covered in this report:

Keytruda (pembrolizumab)
Opdivo (nivolumab)
Tecentriq (atezolizumab)
Imfinzi (durvalumab)
Libtayo (cemiplimab)
ivonescimab (SMT112)
gotistobart (ONC392/BNT316)
oleclumab (MEDI9447)
monalizumab (IPH22)

acasunlimab (GEN1046/BNT311)
volrustomig (MEDI5752)
V940 (mRNA-4157)
tiragolumab
vibostolimab
ociperlimab
domvanalimab
eftilagimod alpha (IMP321)

List of Companies:

Roche
GSK
AstraZeneca
Regeneron
AnaptysBio
Merck & Co.
Bristol Myers Squibb
Incyte
Gilead Sciences
Daiichi Sankyo
BeiGene

BioNTech
Moderna
Genmab
ImmunityBio
CStone
Arcus Biosciences
Immutep
Summit
OncoC4
iTeos Therapeutics
Candel Therapeutics

Executive summary

Current and future treatment algorithm

Research objectives

PD-1/L1-based regimens

Approved therapies
- Advanced NSCLC (Merck & Co.; BMS; Roche; AstraZeneca; Regeneron; Daiichi Sankyo)
- Early-stage NSCLC (Merck & Co.; BMS; Roche; AstraZeneca)
Recently approved and pipeline therapies
- Tevimbra (tislelizumab; BeiGene); Cejemly (sugemalimab; CStone); Zynyz (retifanlimab; Incyte); zimberelimab (Arcus Biosciences)

Anti-CTLA-4 monoclonal antibodies

Gotistobart (BNT316/ONC392; OncoC4/BioNTech)
- Key insights summary

Anti-LAG3 agents

Pipeline therapies
- Fianlimab (Regeneron); Opdualag (relatlimab + nivolumab; BMS); eftilagimod alpha (IMP321; Immutep)

Anti-TIGIT monoclonal antibodies

Pipeline therapies
- Tiragolumab (RG6058; Roche); vibostolimab (MK-7684; Merck & Co.); ociperlimab (BGB-A1217; BeiGene); domvanalimab (AB154; Arcus/Gilead); belrestotug (EOS-448; iTeos/GSK)

Anti-NKG2A/CD73 monoclonal antibodies

Monalizumab (IPH2201; AstraZeneca); oleclumab (AstraZeneca)
- Key insights summary

Bispecific antibodies

Pipeline therapies
- Ivonescimab (SMT112; Summit)
- Acasunlimab (GEN1046/BNT311; Genmab)
- Volrustomig (MEDI5752; AstraZeneca)

Novel immune checkpoint inhibitors (ICIs)

Pipeline therapies
- Cobolimab (GSK4069889/TSR-022; AnaptysBio/GSK)

IL15 receptor agonists

Pipeline therapies
- Anktiva (N-803/nogapendekin alfa inbakicept; ImmunityBio)

Therapeutic vaccines

Pipeline therapies
- V940 (mRNA-4157; Moderna/Merck & Co.); aglatimagene besadenovec (CAN-2409; Candel Therapeutics)

Future treatment trends

Key insights summary

Appendix

KOL details
- KOLs from the USA
- KOLs from Europe

Non-Small Cell Lung Cancer - Immunotherapies - KOL Insight